| scholarly article | Q13442814 |
| P2093 | author name string | Susumu Satomi | |
| Lishomwa C Ndhlovu | |||
| Nigel Killeen | |||
| Ikuo Takeda | |||
| Kazuo Sugamura | |||
| Naoto Ishii | |||
| Kazuko Murata | |||
| Shoji Ine | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3580-3589 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells | |
| P478 | volume | 172 |
| Q56889692 | A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity |
| Q42099442 | A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen |
| Q62040086 | A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2 |
| Q48256829 | A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice. |
| Q34682173 | A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. |
| Q43708681 | Activated T cells express the OX40 ligand: requirements for induction and costimulatory function |
| Q35651705 | Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma |
| Q39655881 | Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice |
| Q38049010 | Advances in the development of cancer immunotherapies |
| Q41233136 | Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice |
| Q79446056 | Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses |
| Q37263111 | Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment |
| Q36440066 | Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. |
| Q38999162 | Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them? |
| Q42185296 | Are we ready for the use of foxp3(+) regulatory T cells for immunodiagnosis and immunotherapy in kidney transplantation? |
| Q34368855 | Association of OX40L polymorphisms with sporadic breast cancer in northeast Chinese Han population |
| Q82542679 | Blockade of OX40-ligand after initial triggering of the T helper 2 response inhibits mercuric chloride-induced autoimmunity |
| Q88109417 | Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression |
| Q26744624 | Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression |
| Q35613421 | CARMA1 is necessary for optimal T cell responses in a murine model of allergic asthma |
| Q36916914 | CD28 costimulation is essential for human T regulatory expansion and function |
| Q34599954 | CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. |
| Q35178495 | CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game |
| Q36085110 | CD4+VEGFR1(HIGH) T cell as a novel Treg subset regulates inflammatory bowel disease in lymphopenic mice |
| Q37573971 | Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. |
| Q35000966 | Cell-intrinsic role for NF-kappa B-inducing kinase in peripheral maintenance but not thymic development of Foxp3+ regulatory T cells in mice |
| Q35627709 | Chemokine receptor CCR7 regulates the intestinal TH1/TH17/Treg balance during Crohn's-like murine ileitis |
| Q81635265 | Co-inhibitory roles for glucocorticoid-induced TNF receptor in CD1d-dependent natural killer T cells |
| Q38897638 | Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go? |
| Q39853193 | Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma |
| Q47155705 | Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer |
| Q39143599 | Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity |
| Q50026646 | Comparative transcriptome analysis reveals distinct genetic modules associated with Helios expression in intratumoral regulatory T cells |
| Q47094157 | Constitutive expression of NF-κB inducing kinase in regulatory T cells impairs suppressive function and promotes instability and pro-inflammatory cytokine production |
| Q33899607 | Control of immunity by the TNFR-related molecule OX40 (CD134) |
| Q37314799 | Critical Role of Transcription Factor PU.1 in the Function of the OX40L/TNFSF4 Promoter in Dendritic Cells |
| Q52631433 | Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation. |
| Q47654169 | Crucial role of OX40/OX40L signaling in a murine model of asthma |
| Q36224132 | Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right |
| Q79967042 | Dendritic cells in cancer immunotherapy |
| Q34601754 | Dendritic cells in the thymus contribute to T-regulatory cell induction |
| Q53308170 | Differential T-cell subset representation in cutaneous squamous cell carcinoma arising in immunosuppressed versus immunocompetent individuals. |
| Q34598797 | Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors |
| Q28730751 | Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression |
| Q36902069 | Dysregulation of CD4+CD25(high) T cells in the synovial fluid of patients with antibiotic-refractory Lyme arthritis. |
| Q46528185 | Effect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB mice. |
| Q54242938 | Effects of OX40-OX40L interaction on the nuclear factor of activated T cells c1 in ApoE-deficient mice. |
| Q44748881 | Enhanced activity of Akt in Teff cells from children with lupus nephritis is associated with reduced induction of tumor necrosis factor receptor-associated factor 6 and increased OX40 expression |
| Q91310928 | Fibroblasts Fuel Immune Escape in the Tumor Microenvironment |
| Q36232655 | Function of tumor necrosis factor receptor family members on regulatory T-cells |
| Q35484886 | GATA3 controls Foxp3⁺ regulatory T cell fate during inflammation in mice |
| Q28080640 | GM-CSF: An immune modulatory cytokine that can suppress autoimmunity |
| Q38787481 | Gene expression in the Gitr locus is regulated by NF-κB and Foxp3 through an enhancer |
| Q43120829 | Genetic control of disease in an experimental model for Sjögren's syndrome |
| Q88797017 | HHV-6B infection, T-cell reconstitution, and graft-vs-host disease after hematopoietic stem cell transplantation |
| Q38770814 | Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities |
| Q46970639 | Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study |
| Q36251301 | Homeostatic T cell proliferation as a barrier to T cell tolerance |
| Q47962577 | IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Regulatory T Cell Suppression To Restrain Experimental Allergic Encephalomyelitis |
| Q91559991 | ILC3-derived OX40L is essential for homeostasis of intestinal Tregs in immunodeficient mice |
| Q57296151 | Identification of a Novel OX40L Dendritic Cell Subset That Selectively Expands Regulatory T cells |
| Q36794126 | Immune regulation and control of regulatory T cells by OX40 and 4-1BB |
| Q34101823 | Indispensable roles of OX40L-derived signal and epistatic genetic effect in immune-mediated pathogenesis of spontaneous pulmonary hypertension |
| Q36948341 | Induced and natural regulatory T cells in the development of inflammatory bowel disease |
| Q47554808 | Innate Lymphoid Cells in HIV/SIV Infections |
| Q37352989 | Integrating costimulatory agonists to optimize immune-based cancer therapies |
| Q47567886 | Interleukin-17A-Induced Human Mesenchymal Stem Cells Are Superior Modulators of Immunological Function. |
| Q27499773 | Life and death as a T lymphocyte: from immune protection to HIV pathogenesis |
| Q36433183 | Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo |
| Q56795939 | Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo |
| Q34615216 | Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases |
| Q37111968 | Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target |
| Q39124619 | Mesenteric lymph nodes contribute to proinflammatory Th17-cell generation during inflammation of the small intestine in mice |
| Q89965514 | Molecular Mechanisms Controlling Foxp3 Expression in Health and Autoimmunity: From Epigenetic to Post-translational Regulation |
| Q35685810 | New insights on OX40 in the control of T cell immunity and immune tolerance in vivo |
| Q90353818 | OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer |
| Q50788096 | OX40 and IL-7 play synergistic roles in the homeostatic proliferation of effector memory CD4⁺ T cells. |
| Q36007580 | OX40 costimulation turns off Foxp3+ Tregs. |
| Q37444300 | OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells |
| Q37273138 | OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. |
| Q40066564 | OX40 is required for regulatory T cell-mediated control of colitis |
| Q35118177 | OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy |
| Q36537926 | OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection |
| Q38555213 | OX40, OX40L and Autoimmunity: a Comprehensive Review. |
| Q37761492 | OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. |
| Q38062540 | OX40L-OX40 Interactions: A Possible Target for Gastrointestinal Autoimmune Diseases |
| Q47162004 | Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses |
| Q28591628 | P2X7 receptor expression levels determine lethal effects of a purine based danger signal in T lymphocytes |
| Q41140315 | PKC-ѳ is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cells |
| Q38819911 | Phenotypical characterization of regulatory T cells in humans and rodents. |
| Q40257557 | Postoperative Helicobacter pylori Infection as a Prognostic Factor for Gastric Cancer Patients after Curative Resection. |
| Q53078816 | Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein. |
| Q24317518 | Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells |
| Q36733476 | Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells |
| Q37727277 | Regeneration of dendritic cells in aged mice |
| Q81610382 | Regulation of OX40 gene expression in graft-versus-host disease |
| Q37051205 | Regulatory CD8+ T cells associated with erosion of immune surveillance in persistent virus infection suppress in vitro and have a reversible proliferative defect |
| Q51044860 | Regulatory T cells are critical to tolerance induction in presensitized mouse transplant recipients through targeting memory T cells. |
| Q34547120 | Regulatory T cells in experimental autoimmune disease |
| Q38000557 | Regulatory T cells in human ovarian cancer |
| Q37412624 | Regulatory T cells overturned: the effectors fight back |
| Q38202988 | Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation |
| Q46934849 | Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy |
| Q36684496 | Roadmap to a better therapeutic tumor vaccine |
| Q31139507 | Secreted and transmembrane 1A is a novel co-stimulatory ligand |
| Q37809163 | Signaling through OX40 enhances antitumor immunity |
| Q34954124 | Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction |
| Q44948990 | Study on the expression of co-stimulatory marker CD134 on CD4+ T cells in HIV-1-infected individuals |
| Q39672063 | Surface expression of inhibitory (CTLA-4) and stimulatory (OX40) receptors by CD4+ regulatory T cell subsets circulating in human malaria. |
| Q41903916 | Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. |
| Q30252330 | T Cells Deficient in the Tyrosine Phosphatase SHP-1 Resist Suppression by Regulatory T Cells |
| Q38778362 | TNFR-Associated Factors 2 and 5 Differentially Regulate the Instructive IL-6 Receptor Signaling Required for Th17 Development. |
| Q45957672 | Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy. |
| Q81999267 | Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis |
| Q38214095 | Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy |
| Q46685523 | The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile |
| Q38684474 | The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice |
| Q90613288 | The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus |
| Q51039680 | The Role of OX40 (CD134) in T-Cell Memory Generation |
| Q38081999 | The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy |
| Q39916867 | The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. |
| Q37415424 | The effect of aging on OX40 agonist-mediated cancer immunotherapy |
| Q38085577 | The nature of activatory and tolerogenic dendritic cell-derived signal II. |
| Q56891562 | The promise and challenges of immune agonist antibody development in cancer |
| Q92916933 | The promise of CD4+FoxP3+ regulatory T-cell manipulation in vivo: applications for allogeneic hematopoietic stem cell transplantation |
| Q34575923 | The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road |
| Q37524064 | The role of OX40-mediated co-stimulation in T-cell activation and survival |
| Q37332068 | The role of TNF superfamily members in T-cell function and diseases |
| Q34441735 | The role of the FOXP3 transcription factor in the immune regulation of allergic asthma. |
| Q34979946 | The significance of OX40 and OX40L to T-cell biology and immune disease. |
| Q36677504 | The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis |
| Q90094371 | Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity |
| Q35790354 | Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. |
| Q37330125 | Thymic OX40 expression discriminates cells undergoing strong responses to selection ligands. |
| Q34171710 | Tissue specific deletion of inhibitor of kappa B kinase 2 with OX40-Cre reveals the unanticipated expression from the OX40 locus in skin epidermis |
| Q55284399 | Tissue-Restricted Adaptive Type 2 Immunity Is Orchestrated by Expression of the Costimulatory Molecule OX40L on Group 2 Innate Lymphoid Cells. |
| Q36914881 | Treg in type 1 diabetes |
| Q37788679 | Tumor Infiltrating Regulatory T Cells: Tractable Targets for Immunotherapy |
| Q89506076 | Tumor necrosis factor receptor family costimulation increases regulatory T-cell activation and function via NF-κB |
| Q36349514 | Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy |
| Q64108546 | Turning the Tide Against Regulatory T Cells |
| Q41852651 | Type I diabetes-associated tolerogenic properties of interleukin-2. |
| Q34549740 | Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts |
| Q30422500 | p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression |
Search more.